Serum profiles of monocyte chemoattractant protein-1 as a biomarker for patients recovering from myocardial infarction

详细信息    查看全文

• 作者：Katarzyna Korybalska (1)
  Ma?gorzata Pyda (2)
  Stefan Grajek (2)
  Magdalena ?anocha (2)
  Andrzej Br?borowicz (1)
  Janusz Witowski (1)
  
• 关键词：Monocyte chemoattractant protein ; 1 ; Acute coronary syndrome ; Left ventricular function ; Restenosis
• 刊名：Clinical Research in Cardiology
• 出版年：2010
• 出版时间：May 2010
• 年：2010
• 卷：99
• 期：5
• 页码：315-322
• 全文大小：276KB
• 参考文献：1. Bonaca MP, Morrow DA (2008) Defining a role for novel biomarkers in acute coronary syndromes. Clin Chem 54:1424-431 CrossRef
  2. O’Donoghue M, Morrow DA (2008) The future of biomarkers in the management of patients with acute coronary syndromes. Curr Opin Cardiol 23:309-14 CrossRef
  3. Charo IF, Taubman MB (2004) Chemokines in the pathogenesis of vascular disease. Circ Res 95:858-66 CrossRef
  4. Braunersreuther V, Mach F, Steffens S (2007) The specific role of chemokines in atherosclerosis. Thromb Haemost 97:714-21
  5. Aukrust P, Halvorsen B, Yndestad A, Ueland T, Oie E, Otterdal K et al (2008) Chemokines and cardiovascular risk. Arterioscler Thromb Vasc Biol 28:1909-919 CrossRef
  6. Frangogiannis NG, Dewald O, Xia Y, Ren G, Haudek S, Leucker T et al (2007) Critical role of monocyte chemoattractant protein-1/CC chemokine ligand 2 in the pathogenesis of ischemic cardiomyopathy. Circulation 115:584-92 CrossRef
  7. Deo R, Khera A, McGuire DK, Murphy SA, Meo Neto JP, Morrow DA et al (2004) Association among plasma levels of monocyte chemoattractant protein-1, traditional cardiovascular risk factors, and subclinical atherosclerosis. J Am Coll Cardiol 44:1812-818 CrossRef
  8. de Lemos JA, Morrow DA, Sabatine MS, Murphy SA, Gibson CM, Antman EM et al (2003) Association between plasma levels of monocyte chemoattractant protein-1 and long-term clinical outcomes in patients with acute coronary syndromes. Circulation 107:690-95 CrossRef
  9. Kervinen H, Manttari M, Kaartinen M, Makynen H, Palosuo T, Pulkki K et al (2004) Prognostic usefulness of plasma monocyte/macrophage and T-lymphocyte activation markers in patients with acute coronary syndromes. Am J Cardiol 94:993-96 CrossRef
  10. Waehre T, Damas JK, Gullestad L, Holm AM, Pedersen TR, Arnesen KE et al (2003) Hydroxymethylglutaryl coenzyme a reductase inhibitors down-regulate chemokines and chemokine receptors in patients with coronary artery disease. J Am Coll Cardiol 41:1460-467 CrossRef
  11. Xu ZM, Zhao SP, Li QZ, Nie S, Zhou HN (2003) Atorvastatin reduces plasma MCP-1 in patients with acute coronary syndrome. Clin Chim Acta 338:17-4 CrossRef
  12. Lewandowski M, Kornacewicz-Jach Z, Millo B, Zielonka J, Czechowska M, Kaliszczak R et al (2008) The influence of low dose atorvastatin on inflammatory marker levels in patients with acute coronary syndrome and its potential clinical value. Cardiol J 15:357-64
  13. de Lemos JA, Morrow DA, Blazing MA, Jarolim P, Wiviott SD, Sabatine MS et al (2007) Serial measurement of monocyte chemoattractant protein-1 after acute coronary syndromes: results from the A to Z trial. J Am Coll Cardiol 50:2117-124 CrossRef
  14. Morimoto H, Takahashi M, Izawa A, Ise H, Hongo M, Kolattukudy PE et al (2006) Cardiac overexpression of monocyte chemoattractant protein-1 in transgenic mice prevents cardiac dysfunction and remodeling after myocardial infarction. Circ Res 99:891-99 CrossRef
  15. Morimoto H, Hirose M, Takahashi M, Kawaguchi M, Ise H, Kolattukudy PE et al (2008) MCP-1 induces cardioprotection against ischaemia/reperfusion injury: role of reactive oxygen species. Cardiovasc Res 78:554-62 CrossRef
  16. Frangogiannis NG, Shimoni S, Chang SM, Ren G, Shan K, Aggeli C et al (2002) Evidence for an active inflammatory process in the hibernating human myocardium. Am J Pathol 160:1425-433
  17. Dewald O, Zymek P, Winkelmann K, Koerting A, Ren G, Abou-Khamis T et al (2005) CCL2/Monocyte chemoattractant protein-1 regulates inflammatory responses critical to healing myocardial infarcts. Circ Res 96:881-89 CrossRef
  18. Dobaczewski M, Frangogiannis NG (2009) Chemokines and cardiac fibrosis. Front Biosci (Schol Ed) 1:391-05
  19. Bolognese L, Neskovic AN, Parodi G, Cerisano G, Buonamici P, Santoro GM et al (2002) Left ventricular remodeling after primary coronary angioplasty: patterns of left ventricular dilation and long-term prognostic implications. Circulation 106:2351-357 CrossRef
  20. Debrunner M, Schuiki E, Minder E, Straumann E, Naegeli B, Mury R et al (2008) Proinflammatory cytokines in acute myocardial infarction with and without cardiogenic shock. Clin Res Cardiol 97:298-05 CrossRef
  21. El Menyar AA (2008) Cytokines and coronary artery disease: the state of the art. Crit Pathw Cardiol 7:139-51
  22. Hansson GK (2005) Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 352:1685-695 CrossRef
  23. Frangogiannis NG (2007) The prognostic value of monocyte chemoattractant protein-1/CCL2 in acute coronary syndromes. J Am Coll Cardiol 50:2125-127 CrossRef
  24. Murakami Y, Kurosaki K, Matsui K, Shimada K, Ikeda U (2003) Serum MCP-1 and VEGF levels are not affected by inhibition of the renin-angiotensin system in patients with acute myocardial infarction. Cardiovasc Drugs Ther 17:249-55 CrossRef
  25. Hoogeveen RC, Morrison A, Boerwinkle E, Miles JS, Rhodes CE, Sharrett AR et al (2005) Plasma MCP-1 level and risk for peripheral arterial disease and incident coronary heart disease: atherosclerosis risk in communities study. Atherosclerosis 183:301-07 CrossRef
  26. Nishiyama K, Ogawa H, Yasue H, Soejima H, Misumi K, Takazoe K et al (1998) Simultaneous elevation of the levels of circulating monocyte chemoattractant protein-1 and tissue factor in acute coronary syndromes. Jpn Circ J 62:710-12 CrossRef
  27. McDermott DH, Yang Q, Kathiresan S, Cupples LA, Massaro JM, Keaney JF Jr et al (2005) CCL2 polymorphisms are associated with serum monocyte chemoattractant protein-1 levels and myocardial infarction in the framingham heart study. Circulation 112:1113-120 CrossRef
  28. Gerszten RE, Garcia-Zepeda EA, Lim YC, Yoshida M, Ding HA, Gimbrone MA Jr et al (1999) MCP-1 and IL-8 trigger firm adhesion of monocytes to vascular endothelium under flow conditions. Nature 398:718-23 CrossRef
  29. Lukacs NW, Strieter RM, Elner V, Evanoff HL, Burdick MD, Kunkel SL (1995) Production of chemokines, interleukin-8 and monocyte chemoattractant protein-1, during monocyte: endothelial cell interactions. Blood 86:2767-773
  30. Hohensinner PJ, Kaun C, Rychli K, Ben Tal CE, Kastl SP, Demyanets S et al (2006) Monocyte chemoattractant protein (MCP-1) is expressed in human cardiac cells and is differentially regulated by inflammatory mediators and hypoxia. FEBS Lett 580:3532-538 CrossRef
  31. Flamant L, Toffoli S, Raes M, Michiels C (2009) Hypoxia regulates inflammatory gene expression in endothelial cells. Exp Cell Res 315:733-47 CrossRef
  32. Bosco MC, Puppo M, Pastorino S, Mi Z, Melillo G, Massazza S et al (2004) Hypoxia selectively inhibits monocyte chemoattractant protein-1 production by macrophages. J Immunol 172:1681-690
  33. Negus RP, Turner L, Burke F, Balkwill FR (1998) Hypoxia down-regulates MCP-1 expression: implications for macrophage distribution in tumors. J Leukoc Biol 63:758-65
  34. Schirmer SH, Fledderus JO, van der Laan AM, van der Pouw-Kraan TC, Moerland PD, Volger OL et al (2009) Suppression of inflammatory signaling in monocytes from patients with coronary artery disease. J Mol Cell Cardiol 46:177-85 CrossRef
  35. Gabrielsen A, Lawler PR, Yongzhong W, Steinbruchel D, Blagoja D, Paulsson-Berne G et al (2007) Gene expression signals involved in ischemic injury, extracellular matrix composition and fibrosis defined by global mRNA profiling of the human left ventricular myocardium. J Mol Cell Cardiol 42:870-83 CrossRef
  36. Kuschert GS, Coulin F, Power CA, Proudfoot AE, Hubbard RE, Hoogewerf AJ et al (1999) Glycosaminoglycans interact selectively with chemokines and modulate receptor binding and cellular responses. Biochemistry 38:12959-2968 CrossRef
  37. Pyda M, Korybalska K, Ksiazek K, Grajek S, Lanocha M, Lesiak M et al (2006) Effect of heparin on blood vascular endothelial growth factor levels in patients with ST-elevation acute myocardial infarction undergoing primary percutaneous coronary intervention. Am J Cardiol 98:902-05 CrossRef
  38. Niu J, Kolattukudy PE (2009) Role of MCP-1 in cardiovascular disease: molecular mechanisms and clinical implications. Clin Sci (Lond) 117:95-09 CrossRef
  39. Nahrendorf M, Swirski FK, Aikawa E, Stangenberg L, Wurdinger T, Figueiredo JL et al (2007) The healing myocardium sequentially mobilizes two monocyte subsets with divergent and complementary functions. J Exp Med 204:3037-047 CrossRef
  40. Tsujioka H, Imanishi T, Ikejima H, Kuroi A, Takarada S, Tanimoto T et al (2009) Impact of heterogeneity of human peripheral blood monocyte subsets on myocardial salvage in patients with primary acute myocardial infarction. J Am Coll Cardiol 54:130-38 CrossRef
  41. Sako H, Miura S, Iwata A, Nishikawa H, Kawamura A, Matsuo K et al (2008) Changes in CCR2 chemokine receptor expression and plasma MCP-1 concentration after the implantation of bare metal stents versus sirolimus-eluting stents in patients with stable angina. Intern Med 47:7-3 CrossRef
  42. Inami N, Nomura S, Shimazu T, Manabe K, Kimura Y, Iwasaka T (2007) Adiponectin incompletely prevent MCP-1-dependent restenosis after percutaneous coronary intervention in patients with coronary artery disease. J Thromb Thrombolysis 24:267-73 CrossRef
  43. Hognestad A, Endresen K, Wergeland R, Mellembakken JR, Mollnes TE, Omland T et al (2005) Inflammatory response and re-stenosis after percutaneous coronary intervention in heart transplant recipients and patients with native atherosclerosis. J Heart Lung Transplant 24:1026-032 CrossRef
  44. Cipollone F, Marini M, Fazia M, Pini B, Iezzi A, Reale M et al (2001) Elevated circulating levels of monocyte chemoattractant protein-1 in patients with restenosis after coronary angioplasty. Arterioscler Thromb Vasc Biol 21:327-34
  45. Usui M, Egashira K, Ohtani K, Kataoka C, Ishibashi M, Hiasa K et al (2002) Anti-monocyte chemoattractant protein-1 gene therapy inhibits restenotic changes (neointimal hyperplasia) after balloon injury in rats and monkeys. FASEB J 16:1838-840
  46. Toutouzas K, Colombo A, Stefanadis C (2004) Inflammation and restenosis after percutaneous coronary interventions. Eur Heart J 25:1679-687 CrossRef
  47. Cavusoglu E, Eng C, Chopra V, Clark LT, Pinsky DJ, Marmur JD (2007) Low plasma RANTES levels are an independent predictor of cardiac mortality in patients referred for coronary angiography. Arterioscler Thromb Vasc Biol 27:929-35 CrossRef
  48. Tarzami ST, Calderon TM, Deguzman A, Lopez L, Kitsis RN, Berman JW (2005) MCP-1/CCL2 protects cardiac myocytes from hypoxia-induced apoptosis by a G (alphai)-independent pathway. Biochem Biophys Res Commun 335:1008-016 CrossRef
  49. Romano M, Diomede L, Sironi M, Massimiliano L, Sottocorno M, Polentarutti N et al (2000) Inhibition of monocyte chemotactic protein-1 synthesis by statins. Lab Invest 80:1095-100
  50. Morikawa S, Takabe W, Mataki C, Kanke T, Itoh T, Wada Y et al (2002) The effect of statins on mRNA levels of genes related to inflammation, coagulation, and vascular constriction in HUVEC. Human umbilical vein endothelial cells. J Atheroscler Thromb 9:178-83
  
• 作者单位：Katarzyna Korybalska (1)
  Ma?gorzata Pyda (2)
  Stefan Grajek (2)
  Magdalena ?anocha (2)
  Andrzej Br?borowicz (1)
  Janusz Witowski (1)
  
  1. Department of Pathophysiology, Poznan University of Medical Sciences, ?wi?cickiego 6, 60-781, Poznan, Poland
  2. 1st Department of Cardiology, Poznan University of Medical Sciences, Poznan, Poland
  

文摘

Background Monocyte chemoattractant protein-1 (MCP-1) plays a key role in the pathogenesis of atherosclerosis and has been proposed as a biomarker for patients with cardiovascular disease. Methods To assess its clinical usefulness, serum MCP-1 concentrations were measured in patients with ST-elevation myocardial infarction (MI) at admission, immediately after percutaneous coronary intervention (PCI), at 24?h, and after 6?months. Results We found no differences in MCP-1 concentrations between patients with acute MI, patients with stable coronary artery disease and healthy individuals. Although median MCP-1 concentrations in patients with MI were similar at admission and after 6?months, there were significant differences between individuals in how MCP-1 levels changed with time. As demonstrated by comparing baseline quartiles of MCP-1, the levels of MCP-1 tended to increase in patients with low MCP-1 concentration at admission, and decrease in patients with initially high MCP-1 levels. We found an inverse correlation between MCP-1 concentration at baseline and the time to reperfusion, and detected a significant decrease in MCP-1 concentration immediately after PCI. We also observed lower MCP-1 concentrations over time in patients who developed restenosis within 6?months. However, we did not confirm the association between MCP-1 concentrations at baseline and a number of previously implicated demographic, clinical and laboratory criteria. Conclusions Our data demonstrate some new aspects of MCP-1 measurement in patients with MI, but do not corroborate many earlier observations.